At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 15 million, including from our Series A in 2021.
Employees: 1-10
Total raised: $48.55M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 07.05.2025 | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.02.2025 | Series B | $28.36M | Andera Par... |
| 14.07.2023 | Series A | $20.2M | - |
Mentions in press and media 19
| Date | Title | Description |
| 26.02.2026 | European Startups Secure Major Funding, AI Dominates, US Expansion Accelerates | European startups attract significant capital. HealthTech leads with nyra.health's €20 million for AI-powered neurological therapy. AI transforms wholesale via Plato, enterprise with VoiceLine, and model training through Rapidata. Strategic... |
| 24.02.2026 | Amid €65 billion lost each year to stroke and dementia in Germany, nyra health secures €20 million to scale digital neurotherapy | Vienna-based nyra health, a provider of an AI-based platform for neurological therapy, announces the completion of a €20 million Series A financing round to further expand its technology platform in the DACH region, accelerate its expansion... |
| 27.02.2025 | Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder | First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutions Phase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity (neurogenic bladder) -related incontinence foll... |
| 27.02.2025 | Avancée majeure pour EG 427 avec le premier patient traité par EG110A, la première thérapie génique à base d’un vecteur herpétique non réplicatif pour le traitement de la vessie neurogène | Premier patient traité avec succès dans l’étude clinique EG110A menée dans quatre institutions médicales de premier plan aux États-Unis Étude de phase 1b/2a visant à recruter 16 patients atteints d’incontinence liée à l’hyperactivité du dét... |
| 20.02.2025 | EG 427 Secures €27 Million to Revolutionize Neurology Treatments | In a significant leap for biotechnology, Paris-based startup EG 427 has successfully closed a €27 million Series B financing round. This funding, co-led by Andera Partners and Bpifrance, marks a pivotal moment for the company as it aims to ... |
| 20.02.2025 | EG 427 Raises €27M in Series B Funding | EG 427, a Paris, France-based biotechnology company for the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, raised €27M in Series B funding. The round was co-led by Andera Partners and Bpifrance, with ... |
| 20.02.2025 | EG 427 lève 27 millions d’euros lors d’un tour de financement de série B mené conjointement par Andera Partners et Bpifrance pour financer son étude clinique en cours et le développement de sa platefo... | Le fonds spécialisé SCI Ventures, soutenu par les principales fondations dédiées aux blessés médullaires, ainsi que des investisseurs historiques, ont également participé à ce tour de table. Les fonds levés permettront de financer l’étude d... |
| 20.02.2025 | EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development | Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this round Proceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Open... |
| 20.02.2025 | EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development | EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful closing of a €27 million Series B financing round co-led by Andera Partners an... |
| 20.02.2025 | EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development | Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this roundProceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Opens... |
Show more